Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer’s Disease
3.2 points may not sound like much but it should be kept in mind that the MMSE is a 30-point scale.
Five patients with mild to moderate AD received oral benfotiamine (300 mg daily) over 18 months. All patients were examined by positron emission tomography with Pittsburgh compound B (PiB-PET) and exhibited positive imaging with β-amyloid deposition, and three received PiB-PET imaging at follow-up. The five patients exhibited cognitive improvement as assayed by the Mini-Mental Status Examination (MMSE) with an average increase of 3.2 points at month 18 of benfotiamine administration.
3.2 points may not sound like much but it should be kept in mind that the MMSE is a 30-point scale.